Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price1.20 USD
Ethical score70.0/100
RatingAVOID
Our investment reviews on this name
2026-08-22Read Markup1.01+18.8% to today ✓
2026-07-02Read Markdown1.01+18.8% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Actinium Pharmaceuticals, Inc. holds its Markup at $1.20. The statistical read favours the buyers, held for 86 days.
As held on the ledger · 2026-09-21
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 86 days
Price at the screen
$1.20
Valuation
N/A trailing · -2.89 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-0.05
The Workings
Five Screens, Shown in Full
Does not pass. Cash ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
4.17%
Below 33%
Interest-bearing debt is just 4.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
118.13%
Below 33%
Interest-bearing cash and securities are 118.1% of assets, above the one-third limit.
Fail
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Actinium Pharmaceuticals,'s business is fine, but its cash and interest-bearing securities are about 118% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits +275% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ATNM trades on NYSE American. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markup$1.20+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (5 analysts) rates it buy, with a mean price target of $5.
2026-09-24Markup$1.20+18.8%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (5 analysts) rates it buy, with a mean price target of $5.
2026-08-22Markup · changed$1.01+0.0%Entry 5
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (5 analysts) rates it buy, with a mean price target of $5.
2026-07-22Markdown$1.01+0.0%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (5 analysts) rates it buy, with a mean price target of $5.
2026-07-18Markdown$1.01+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 40%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (5 analysts) rates it buy, with a mean price target of $5.
2026-07-03Markdown$1.01+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$1.01Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$1.34
-21.3%
·
$787
-21.3%
2 months
$1.08
-2.3%
·
$977
-2.3%
3 months
$1.13
-6.6%
·
$934
-6.6%
6 months
$1.45
-27.2%
·
$728
-27.2%
1 year
$1.77
-40.4%
·
$596
-40.4%
2 years
$7.99
-86.8%
·
$132
-86.8%
3 years
$8.28
-87.3%
·
$127
-87.3%
5 years
$8.51
-87.6%
·
$124
-87.6%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever ATNM does next, these words stay.
Actinium Pharmaceuticals, Inc. · ATNM · Markup · $1.20
Recorded 2026-09-21 · before the outcome · scored mechanically